RecruitingObesity
Insulin Regulation of Lipolysis and Lipolysis Proteins
Eligible age
18–55 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Men and Women between the ages of 18 and 55.
- ✓ Women will be premenopausal
- ✓ Non obese adults BMI between 18-25
- ✓ Obese BMI 30-38
You may not qualify if…
- ✕ Initiation in patients with established New York Heart Associations (NYHA) class III or IV Heart failure.
- ✕ Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOSE.
Where it's recruiting
Minnesota
Rochester
Source: ClinicalTrials.gov · NCT03866408 · last updated 2026-01-28